免疫抑制性CD10+ALPL+中性粒细胞通过介导T细胞不可逆耗竭促进肝细胞癌抗PD-1治疗耐药
该研究以单细胞分辨率分析接受抗PD-1免疫治疗的肝细胞癌患者肿瘤组织转录组,结合流式细胞术、组织病理学及大鼠模型验证,发现CD10+ALPL+中性粒细胞与抗PD-1治疗耐药相关,其通过诱导T细胞数量、频率及基因谱的「不可逆」耗竭发挥强免疫抑制活性;机制上肿瘤分泌的NAMPT经NTRK1重编程CD10+ALPL+中性粒细胞并维持其未成熟状态。
要点
- CD10+ALPL+中性粒细胞与肝细胞癌抗PD-1治疗耐药相关。
- 该群中性粒细胞诱导T细胞数量、频率及基因谱的「不可逆」耗竭。
- 肿瘤分泌NAMPT经NTRK1重编程CD10+ALPL+中性粒细胞,维持其未成熟状态并抑制成熟与活化。
核心结论
- CD10+ALPL+中性粒细胞通过诱导T细胞「不可逆」耗竭参与肿瘤免疫逃逸,使肿瘤逃避抗PD-1治疗的预期效果。
- 该结果为阐明特定细胞群体及免疫治疗耐药的分子机制提供了新的理论依据。
- 作者认为,靶向这些细胞联合现有免疫治疗可被视为一种可能更有效的治疗策略。
研究设计与样本
- 研究对计划接受以抗PD-1为基础的免疫治疗的肝细胞癌患者肿瘤组织进行单细胞分辨率转录组分析。
- 采用流式细胞术和组织病理学分析进行比较分析与实验验证,并在患者和大鼠模型中鉴定与抗PD-1治疗耐药相关的细胞亚群。
- 采用基于TurboID的邻近标记方法探讨肝细胞癌微环境重编程的机制。
主要发现
- 鉴定出CD10+ALPL+中性粒细胞与抗PD-1治疗耐药相关。
- CD10+ALPL+中性粒细胞在细胞数量、频率和基因谱方面诱导T细胞明显的「不可逆」耗竭,表现出强免疫抑制活性。
- 肿瘤细胞诱导CD10+ALPL+中性粒细胞,即肿瘤分泌的NAMPT通过NTRK1重编程CD10+ALPL+中性粒细胞,使其维持未成熟状态并抑制其成熟和活化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Remodeling the tumor microenvironment is a critical strategy for treating advanced hepatocellular carcinoma (HCC). Yet, how distinct cell populations in the microenvironment mediate tumor resistance to immunotherapies, such as anti-PD-1, remains poorly understood. METHODS: We analyzed the transcriptomic profile, at a single-cell resolution, of tumor tissues from patients with HCC scheduled to receive anti-PD-1-based immunotherapy. Our comparative analysis and experimental validation using flow cytometry and histopathological analysis uncovered a discrete subpopulation of cells associated with resistance to anti-PD-1 treatment in patients and a rat model. A TurboID-based proximity labeling approach was deployed to gain mechanistic insights into the reprogramming of the HCC microenvironment. RESULTS: We identified CD10+ALPL+ neutrophils as being associated with resistance to anti-PD-1 treatment. These neutrophils exhibited a strong immunosuppressive activity by inducing an apparent "irreversible" exhaustion of T cells in terms of cell number, frequency, and gene profile. Mechanistically, CD10+ALPL+ neutrophils were induced by tumor cells, i.e., tumor-secreted NAMPT reprogrammed CD10+ALPL+ neutrophils through NTRK1, maintaining them in an immature state and inhibiting their maturation and activation. CONCLUSIONS: Collectively, our results reveal a fundamental mechanism by which CD10+ALPL+ neutrophils contribute to tumor immune escape from durable anti-PD-1 treatment. These data also provide further insights into novel immunotherapy targets and possible synergistic treatment regimens. IMPACT AND IMPLICATIONS: Herein, we discovered that tumor cells reprogrammed CD10+ALPL+ neutrophils to induce the "irreversible" exhaustion of T cells and hence allow tumors to escape from the intended effects of anti-PD-1 treatment. Our data provided a new theoretical basis for the elucidation of special cell populations and revealed a molecular mechanism underpinning resistance to immunotherapy. Targeting these cells alongside existing immunotherapy could be looked at as a potentially more effective therapeutic approach.
引用
- Meng Y, Ye F, Nie P, et al. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells. J Hepatol. 2023. PMID: 37689322. doi:10.1016/j.jhep.2023.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。